Current microbiome testing still faces major barriers to routine clinical use. Stool-based analyses often require weeks to return results, while the gut microbiome itself is highly dynamic and can change rapidly in response to diet, sleep, mood and other factors. In addition, conventional reports frequently provide complex taxonomic data, such as bacterial abundances and diversity indexes, that many clinicians find difficult to translate into practical interventions. 

In this interview, Amine Zorgani explains how SwipeBiome aims to address these limitations by moving beyond traditional stool testing toward real-time microbiome prediction based on patient metadata. The goal is to deliver clinically validated, actionable recommendations that physicians can use directly, including targeted interventions to improve drug response or reduce potential treatment-related side effects.